An in vivo battery for identifying endocrine modulators that are estrogenic or dopamine regulators

Fundamental and Applied Toxicology

Volumn 33, Issue 2, 1996, Pages 182-195

  O'Connor, John C ^a   Cook, Jon C ^a   Craven, Suzanne C ^a   Van Pelt, Carolyn S ^a   Obourn, John D ^a  

^a DUPONT COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIESTROGEN; ESTRADIOL; ESTRIOL; ESTROGEN; ESTROGEN RECEPTOR; FULVESTRANT; GROWTH HORMONE; HALOPERIDOL; PROGESTERONE RECEPTOR; PROLACTIN; RESERPINE; TAMOXIFEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CYTOLOGY; DOSE RESPONSE; ENDOMETRIUM; ESTROGEN ACTIVITY; FEMALE; INTRAPERITONEAL DRUG ADMINISTRATION; METHODOLOGY; NONHUMAN; OVARIECTOMY; PROLACTIN BLOOD LEVEL; RAT; RECEPTOR DENSITY; SCREENING; UTERUS FLUID; UTERUS WEIGHT;

ANIMALIA; RODENTIA;

EID: 26844497292     PISSN: 02720590     EISSN: None     Source Type: Journal    
DOI: 10.1006/faat.1996.0156     Document Type: Article

References (60)

1. Adami, H.-O., Lipworth, L., Titus-Ernstoff, L., Hsieh, C.-C., Hanberg, A., Ahlborg, U., Baron, J., and Trichopoulos, D. (1995). Organochlorine compounds and estrogen-related cancers in women. Cancer Causes Control 6, 551-566.
2. Ahlborg, U. G., Lipworth, L., Titus-Ernstoff, L., Hsieh, C.-C., Hanberg, A., Baron, J., Trichopoulos, D., and Adami, H.-O. (1995). Organochlorine compounds in relation to breast cancer, endometrial cancer, and endometriosis: An assessment of the biological and epidemiological evidence. Crit. Rev. Toxicol. 25, 463-531.
3. Alison, R. H., Capen, C. C., and Prentice, D. E. (1994). Neoplastic lesions of questionable significance to humans. Toxicol. Pathol. 22, 179-186.
4. Allen, E., and Doisy, E. A. (1923). Preliminary report on its localization, extraction and partial purification, and action in test animals. J. Am. Med. Assoc. 8, 819-821.
5. Astwood, E. B. (1938). A six-hour assay for the quantitative determination of estrogen. Endocrinology 23, 25-31.
6. Beato, M., Herelich, P., and Schultz, G. (1995). Steroid receptors: Many actors in search of a plot. Cell 83, 851-857.
7. Bhattacharyya, N., Ramsammy, R., Batman, E., Hollis, V. W., and Anderson, W. A. (1994). Protooncogene, growth factor, growth factor receptor, and estrogen and progesterone receptor gene expression in the immature rat uterus after treatment with estrogen and tamoxifen. J. Submicrosc. Cytol. Pathol. 26, 147-162.
8. Branham, W. S., Leamons, M. L., and Sheehan, D. M. (1988a). Estrogen-and antiestrogen-induced ornithine decarboxylase activity and uterine growth in the rat. J. Steroid Biochem. 29, 153-159.
9. Branham, W. S., Lyn-Cook, B. D., Andrews, A., and Sheehan, D. M. (1993a). Growth of separated and recombined neonatal rat uterine luminal epithelium and stroma on extracellular matrix: Effects of in vivo tamoxifen exposure. In Vitro Cell Dev. Biol. 29A, 408-414.
10. Branham, W. S., Zehr, D. R., Chen, J. J., and Sheehan, D. M. (1988b). Postnatal uterine development in the rat: Estrogen and antiestrogen effects on luminal epithelium. Teratology 38, 29-36.
11. Branham, W. S., Zehr, D. R., and Sheehan, D. M. (1993b). Differential sensitivity of rat uterine growth and epithelium hypertrophy to estrogens and antiestrogens. Proc. Soc. Exp. Biol. Med. 203, 297-303.
12. Clark, J. H., and Mani, S. K. (1994). Actions of ovarian steroid hormones. In The Physiology of Reproduction (E. Knobil and J. D. Neill, Eds.), pp. 1011-1059. Raven Press, New York.
13. Clark, J. H., and Markaverich, B. M. (1983). The agonistic and antagonistic effects of short acting estrogens: A review. Pharmacol. Ther. 21, 429-453.
14. Clute, E. (1995). Tamoxifen - Breast cancer preventive or human carcinogen? Toxicol. Ind. Health 11, 503-510.
15. Cohen, H., Pageaux, J.-F., Melinand, C., Fayard, J.-M., and Laugier, C. (1993). Normal rat uterine stromal cells in continuous culture: Characterization and progestin regulation of growth. Eur. J. Cell. Biol. 61, 116-125.
16. Colborn, T., Saal, F. S. V., and Soto, A. M. (1993). Developmental effects of endocrine-disrupting chemicals in wildlife and humans. Environ. Health Perspect. 101, 378-384.
17. Davis, B. (Ed.) (1993). Female Reproductive Toxicology. Academic Press, San Diego.
18. DeGroot, L. J. (Ed.) (1995). Endocrinology, pp. 341-367. Saunders, Philadelphia.
19. Dickson, R. B., Johnson, M. D., Bano, M., Shi, E., Kurebayashi, J., Ziff, B., Martinez-Lacaci, L, Amundadottir, L. T., and Lippman, M. E. (1992). Growth factors in breast cancer: Mitogenesis to transformation. J. Steroid Biochem. Mol. Biol. 43, 69-78.
20. Durbin, P. W., Williams, M. H., Jeung, N., and Arnold, J. S. (1966). Development of spontaneous mammary tumors over the life-span of the female Charles River (Sprague-Dawley) rat: The influence of ovariectomy, thyroidectomy, and adrenalectomy-avariectomy. Cancer Res. 26 (Part 1), 400-411.
21. Edgren, R. A. (1994). Issues in animal pharmacology. In Pharmacology of the Contraceptive Steroids. (J. W. Goldzieher, Ed.), pp. 81-97. Raven Press, New York.
22. FDA Advisory Committee Report on Antipsychotic Drugs (August 12, 1977).
23. Goodman Gilman, A. (1990). Goodman and Gilman's The Pharmacological Basis of Therapeutics. Pergamon, New York.
24. Greaves, P. (1990). Factors affecting development and growth of mammary neoplasms. In Histopathology of Preclinical Toxicity Studies: Interpretation and Relevance in Drug Safety Evaluation. pp. 64-69. Elsevier, Amsterdam.
25. Henderson, B. E., Ross, R. K., and Pike, M. C. (1993). Hormonal chemoprevention of cancer in women. Science 259, 633-638.
26. Ignar-Trowbridge, D. M., Nelson, K. R., Bidwell, M. C., Curtis, S. W., Washburn, T. F., McLachlan, J. A., and Korach, K. (1992). Coupling of dual signalling pathways: Epidermal growth factor action involves the estrogen receptor. Proc. Natl. Acad. Sci. USA 89, 4658-4662.
27. Jansson, J.-O., Staffan, E., and Isaksson, O. (1985). Sexual dimorphism in the control of growth hormone secretion. Endocrine Rev. 6, 128-150.
28. Jones, R. C., and Edgren, R. A. (1973). The effects of various steroids on the vaginal histology in the rat. Fertil. Steril. 24, 284-291.
29. Jordan, C. V. (1995). An overview of considerations for the testing of tamoxifen as a preventive for breast cancer. Ann. NY Acad. Sci. 768, 141-147.
30. Kangas, Lauri. (1992). Agonistic and antagonistic effects of antiestrogens in different organs. Acta. Oncol. 31, 143-146.
31. Katzenellenbogen, B. S., and Gorski, J. (1975). The Biochemical Actions of Hormones. Academic Press, New York.
32. Kaye, A. M., Sheratzky, D., and Lindner, H. R. (1972). Kinetics of DNA synthesis in immature rat uterus: Age dependence and estradiol stimulation. Biochim. Biophys. Acta 261, 475-486.
33. Key, T., and Reeves, G. (1994). Organochlorines in the environment and breast cancer. Br. Med. J. 308, 1520-1521.
34. Kraus, W. L., and Katzenellenbogen, B. S. (1993). Regulation of progesterone receptor gene expression and growth in the rat uterus: Modulation of estrogen actions by progesterone and sex steroid hormone antagonists. Endocrinology 132, 2371-2379.
35. Krieger, N., Wolff, M. S., Hiatt, R. A., Rivera, M., Vogelman, J., and Orentriech, N. (1994). Breast cancer and serum organochlorines: A prospective study among white, black, and Asian women. J. Natl. Cancer Inst. 86, 589-599.
36. Kronenberg, M. S., and Clark, J. H. (1985). Changes in keratin expression during the estrogen-mediated differentiation of rat vaginal epithelium. Endocrinology 117, 1480-1489.
37. Lee, Y. H., Howe, R. S., Sha, S.-J., Teuscher, C., Sheehan, D. M., and Lyttle, R. (1989). Estrogen regulation of an eosinophil chemotactic factor in the immature rat uterus. Endocrinology 125, 3022-3028.
38. Macleod, R. M., and Lehmeyer, J. E. (1974). Studies on the mechanism of the dopamine-mediated inhibition of prolactin secretion. Endocrinology 94, 1077-1085.
39. Manni, A., Baker, R., Arafah, B. M., and Pearson, O. H. (1981). Uterine oestrogen and progesterone receptors in the ovariectomized rat. J. Endocrinol. 91, 281-287.
40. Martin, L., and Claringbold, P. J. (1958). A highly sensitive assay for oestrogens. Nature 181, 620-621.
41. Meites, J. (1972a). Regulation of prolactin and estrogen to mammary cancer in the rat in response to estrogen. Arch. Pathol. 33, 334-356.
42. Meites, J. (1972b). Relation of prolactin and estrogen to mammary tumorigenesis in the rat. J. Natl. Cancer Inst. 48, 1217-1224.
43. Neumann, F. (1991). Early indicators for carcinogenesis in hormone-sensitive organs. Mutat. Res. 248, 341-356.
44. Newman, C. B., Cosby, H., Friesen, H. G., Feldman, M., Cooper, P., De Crescito, V., Pilon, M., and Kleinberg, D. L. (1987). Evidence for a nonprolactin, non-growth-hormone mammary mitogen in the human pituitary gland. Proc. Natl. Acad. Sci. USA 84, 8110-8114.
45. Obourn, J. D., Koszewski, N. J., Notides, A. C. (1994). Hormone-and DNA-binding mechanisms of the recombinant human estrogen receptor. Biochemistry 32, 6229-6236.
46. Safe, S. H. (1995). Environmental and dietary estrogens and human health: Is there a problem? Environ. Health Perspect. 103, 346-351.
47. Scatchard, G. (1949). The attractions of proteins for small molecules and ions. Ann. NY Acad. Sci. 51, 660-672.
48. Schardein, J. L. (1993). Hormones and Hormonal Antagonists, In Chemically Induced Birth Defects. pp. 271-339. Dekker, New York.
49. Schyve, P. M., Smithline, F., and Meltzer, H. Y. (1978). Neuroleptic-induced prolactin level elevation and breast cancer. Arch. Gen. Psychiatry 35, 1291-1301.
50. Shupnik, M. A., Gordon, M. S., and Chin, W. (1989). Tissue-specific regulation of rat estrogen receptor mRNAs. Mol. Endocrinol. 3, 660-665.
51. Soto, A. M., Lin, T. M., Justicia, H., Silvia, R. M., and Sonnenschein, C. (1992) An 'in culture' bioassay to assess the estrogenicity of xenobiotics (E-screen), In Advances in Modern Environmental Toxicology. Chemically-induced Alterations in Sexual and Functional Development: The Wildlife/Human Connection. Vol. 21. pp. 295-309. Princeton Sci. Pub., Princeton.
52. Stormshak, F., Leake, R., Wertz, N., and Gorski, J. (1976). Stimulatory and inhibitory effects of estrogen on uterine DNA synthesis. Endocrinology 99, 1501-1511.
53. Villalobos, M., Olea, N., Brotons, J. A., Loea-Serrano, M. F., Almodovar, J. M. R., and Pedraza, V. (1995). The E-screen assay: A comparison of different MCF-7 cell stocks. Environ. Health Perspect. 103, 844-850.
54. Wakeling, A. E., Dukes, M., and Bowler J. (1991). A potent specific pure antiestrogen with clinical potential. Cancer Res. 51, 3867-3873.
55. Welch, R. M., Levin, W., and Conney, A. H. (1969). Estrogenic action of DDT and its analogs. Toxicol. Appl. Pharmacol. 14, 358-367.
56. Welsch, C. W. (1983). Hormones and murine mammary tumorigenesis: An historical perspective. In Hormonal Regulation of Experimental Mammary Tumors (B. S. Leung, Ed.). pp. 1-29. Eden Press, Montreal.
57. Welsch, C. W. (1985). Host factors affecting the growth of carcinogen-induced rat mammary carcinomas: A review and tribute to Charles Brenton Huggins. Cancer Res. 45, 3415-3443.
58. Welsch, C. W. (1986) Interrelationship between dietary fat and endocrine processes in mammary gland tumorigenesis. In Dietary Fat and Cancer (A. Rogers, D. Birt, E. Mettlin, and C. Ip, Eds.), pp. 623-654. A. R. Liss, New York.
59. Welsch, C. W., Adams, C., Lambrecht, L. K., and Brooks, C. K. (1977). 17β-estradiol and envoid mammary tumorigenesis in C3H/HeJ female mice: Counteraction by concurrent 2-bromo-α-ergocriptine. Br. J. Can. 35, 322-328.
60. Wolff, M. S., Toniolo, P. G., Leel, E. W., Rivera, M., and Dubin, N. (1993). Blood levels of organochlorine residues and risk of breast cancer. J. Natl. Cancer Inst. 85, 648-652.